These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 24421336)

  • 1. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.
    Fibriansah G; Tan JL; Smith SA; de Alwis AR; Ng TS; Kostyuchenko VA; Ibarra KD; Wang J; Harris E; de Silva A; Crowe JE; Lok SM
    EMBO Mol Med; 2014 Mar; 6(3):358-71. PubMed ID: 24421336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas.
    Andrade DV; Warnes C; Young E; Katzelnick LC; Balmaseda A; de Silva AM; Baric RS; Harris E
    Sci Rep; 2019 Nov; 9(1):16258. PubMed ID: 31700029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody affinity versus dengue morphology influences neutralization.
    Fibriansah G; Lim EXY; Marzinek JK; Ng TS; Tan JL; Huber RG; Lim XN; Chew VSY; Kostyuchenko VA; Shi J; Anand GS; Bond PJ; Crowe JE; Lok SM
    PLoS Pathog; 2021 Feb; 17(2):e1009331. PubMed ID: 33621239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins.
    Fibriansah G; Tan JL; Smith SA; de Alwis R; Ng TS; Kostyuchenko VA; Jadi RS; Kukkaro P; de Silva AM; Crowe JE; Lok SM
    Nat Commun; 2015 Feb; 6():6341. PubMed ID: 25698059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
    VanBlargan LA; Milutinovic PS; Goo L; DeMaso CR; Durbin AP; Whitehead SS; Pierson TC; Dowd KA
    J Virol; 2021 Nov; 95(23):e0095621. PubMed ID: 34549976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.
    Widman DG; Young E; Nivarthi U; Swanstrom JA; Royal SR; Yount BL; Debbink K; Begley M; Marcet S; Durbin A; de Silva AM; Messer WB; Baric RS
    Sci Rep; 2017 Dec; 7(1):17169. PubMed ID: 29215033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA; Mukherjee S; Dowd KA; Durbin AP; Whitehead SS; Pierson TC
    PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.
    Zhao H; Xu L; Bombardi R; Nargi R; Deng Z; Errico JM; Nelson CA; Dowd KA; Pierson TC; Crowe JE; Diamond MS; Fremont DH
    J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31757867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries.
    Moreland NJ; Susanto P; Lim E; Tay MYF; Rajamanonmani R; Hanson BJ; Vasudevan SG
    Int J Mol Sci; 2012; 13(3):2618-2635. PubMed ID: 22489114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.
    Fibriansah G; Ibarra KD; Ng TS; Smith SA; Tan JL; Lim XN; Ooi JS; Kostyuchenko VA; Wang J; de Silva AM; Harris E; Crowe JE; Lok SM
    Science; 2015 Jul; 349(6243):88-91. PubMed ID: 26138979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
    J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.
    Chan AH; Tan HC; Chow AY; Lim AP; Lok SM; Moreland NJ; Vasudevan SG; MacAry PA; Ooi EE; Hanson BJ
    PLoS One; 2012; 7(4):e33451. PubMed ID: 22509258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
    Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
    Wahala WM; Huang C; Butrapet S; White LJ; de Silva AM
    J Virol; 2012 Apr; 86(7):4019-23. PubMed ID: 22278250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.